Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abelacimab (Primary) ; Abelacimab (Primary)
  • Indications Embolism; Ischaemic stroke; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Anthos Therapeutics

Most Recent Events

  • 29 Oct 2021 Results assessing the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single dose intravenous and multiple dose subcutaneous administration of abelacimab in healthy volunteers (ANT-003 study) and patients with atrial fibrillation (ANT-004 study), respectively, published in the Journal of Thrombosis and Haemostasis.
  • 23 Mar 2021 Status changed from active, no longer recruiting to completed.
  • 01 Mar 2021 Planned End Date changed from 1 Mar 2021 to 11 Mar 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top